Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
TransMedics Q1 2026 Earnings Call - Revenue Growth Hits 21% as CHOPS and Gen 3.0 Drive Strategic Expansion
TransMedics delivered a solid Q1 2026 with total revenue of $174 million, up 21% year-over-year, driven by strong liver performance and growing OCS case volumes. The company is aggressively investing ...
- Total revenue for Q1 2026 reached $174 million, representing 21% year-over-year growth and 8% sequential growth, led by strong liver performance and increased OCS case volumes.
- U.S. transplant product revenue grew 22% year-over-year to $102 million, while international revenue surged 39% year-over-year to $6 million, driven by heart and lung adoption.
- Adjusted operating profit of $18.1 million reflected a 10.4% operating margin, down from prior periods due to strategic investments in R&D and international expansion.
- +7 more takeaways
Revolve Group Q1 2026 Earnings Call - Accelerating Growth and Strategic Investments Drive Market Share Gains
Revolve Group delivered a strong first quarter in 2026, with net sales rising 16% year-over-year to $343 million, marking its fastest growth rate in nearly four years. The company's strategic investme...
- Net sales increased 16% year-over-year to $343 million, the highest growth rate in nearly four years, with a 5-point sequential improvement from Q4 2025.
- Diluted earnings per share rose 25% year-over-year to $0.20, reflecting strong bottom-line performance despite increased marketing investments.
- International net sales grew 20% year-over-year, marking the 13th consecutive quarter of international growth outpacing the U.S., despite a slowdown in the Middle East.
- +7 more takeaways
DaVita Q1 2026 Earnings Call - Raised Guidance on Volume Surge and Fresenius Transfers
DaVita delivered a sharp first quarter, beating expectations on revenue per treatment and cost discipline while quietly capturing market share from Fresenius clinic closures. The company lifted full-y...
- Full-year adjusted operating income guidance raised to $2.15B-$2.25B, up $40M midpoint, driven by volume and labor efficiency.
- Full-year adjusted EPS guidance lifted to $14.10-$15.20, reflecting higher volume and lower patient care costs.
- Treatment volume guidance increased from flat to +25-50 basis points, with roughly half attributed to Fresenius clinic transfers.
- +9 more takeaways
American Coastal Insurance Corporation Q1 2026 Earnings Call - Discipline Wins as Soft Market Pressures Rates But Margins Hold
American Coastal Insurance (ACIC) reported Q1 2026 net income of $19.3 million, driven by a 66% combined ratio that reflects sharp underwriting discipline in a rapidly softening commercial property ma...
- Q1 2026 net income came in at $19.3 million, with core income also at $19.3 million, down $1.4 million year-over-year as net premium earned declined, though this was partially offset by lower total expenses.
- The combined ratio stood at 66%, just 1 point higher than the prior year, while the non-GAAP underlying combined ratio was 68.3%, demonstrating stable underwriting margins despite a softening commercial property market.
- CEO Bennett Bradford Martz confirmed average account rate decreases are distorting premium growth, but policy counts and exposure bases actually increased year-over-year, signaling strong account retention and market leadership defense.
- +7 more takeaways
Joby Aviation Q1 2026 Earnings Call - EIPP Selection and Manufacturing Ramp Accelerate
Joby Aviation's Q1 2026 results underscore a critical inflection point in the eVTOL commercialization timeline. The company secured its spot in the White House-backed EIPP program across 11 states, en...
- Joby selected for the White House-backed EIPP program across 11 states, including Texas, New York, and Florida, enabling pre-certification passenger operations this year.
- Successful demonstration flights connected JFK to Manhattan heliports and operated within Class B airspace, proving operational maturity in dense urban environments.
- Manufacturing is accelerating with parts being produced for the ninth conforming aircraft and a third shift added to composites and automated fiber placement teams.
- +7 more takeaways
SuRo Capital Q1 2026 Earnings Call - NAV Surges 76% Amid Strategic Magnetar Partnership
SuRo Capital delivered its largest quarterly NAV increase in history, jumping 76% to $14.24 per share, driven by massive unrealized gains across a concentrated portfolio of high-growth private compani...
- SuRo Capital’s NAV surged 76% quarter-over-quarter from $8.09 to $14.24 per share, marking the largest quarterly increase in company history.
- The valuation jump was primarily driven by a $6.25 per share increase in unrealized appreciation across the portfolio, partially offset by a $0.16 per share net investment loss.
- Top five holdings, including Whoop, OpenAI, and Vast Data, now represent approximately 72% of the investment portfolio, highlighting a highly concentrated strategy.
- +7 more takeaways
Live Nation Q1 2026 Earnings Call - Global Supply Surge and Venue Nation Expansion Offset Ticketing Headwinds
Live Nation reported a strong start to 2026, driven by a global expansion in concert supply and robust demand across all venue types. CEO Michael Rapino highlighted that the "pie" of touring activity ...
- Global supply of touring artists is expanding rapidly, with strong growth across all venue types from clubs to stadiums, driven by international markets including Latin America, Asia, and K-pop acts.
- Amphitheaters are rebounding strongly in 2026, with double-digit growth in show counts and ticket sales, offsetting last year’s supply-side stumbles and demonstrating resilient demand.
- Venue Nation strategy is accelerating, with a focus on both building new venues and partnering with existing sports stadiums in Latin America to lock in revenue streams with lower capital intensity.
- +7 more takeaways
Klaviyo Q1 2026 Earnings Call - AI Agents Drive Record Margins and Enterprise Consolidation
Klaviyo delivered a quarter that underscored the shift from basic marketing automation to autonomous consumer relationship management. Revenue grew 28% year-over-year to $358 million, while non-GAAP o...
- Revenue grew 28% year-over-year to $358 million, beating expectations and driving a raise in full-year guidance.
- Non-GAAP operating margin expanded to a record 16%, marking the highest level since the company went public.
- Klaviyo achieved its first quarter of positive GAAP operating margin since its IPO, driven by margin expansion and reduced stock-based compensation.
- +7 more takeaways
Jazz Pharmaceuticals Q1 2026 Earnings Call - Record Revenue Driven by Zepzelca and XYWAV Momentum
Jazz Pharmaceuticals delivered a record first quarter of 2026, with total revenues surging 19% year-over-year to $1.1 billion. The growth was broad-based, fueled by double-digit expansions across all ...
- Total first-quarter 2026 revenue hit a record $1.1 billion, reflecting 19% year-over-year growth.
- Zepzelca sales surged 60% to $101 million, driven by rapid uptake in the first-line maintenance setting for extensive stage small cell lung cancer.
- XYWAV net product sales increased 18% to $408 million, with 425 net patient adds and 16,600 active patients.
- +7 more takeaways
Neurocrine Biosciences Q1 2026 Earnings Call - Commercial Momentum Accelerates as Pipeline Catalysts Loom in 2027
Neurocrine Biosciences delivered a quarter of undeniable momentum, with total revenue surpassing $800 million for the first time in company history. INGREZZA continues to defy gravity nine years post-...
- Total revenue exceeded $800 million for the first time in company history, representing a 44% year-over-year increase.
- INGREZZA sales reached $657 million, up 20% year-over-year, with management reaffirming 2026 guidance of $2.7 to $2.8 billion.
- CRENESSITY sales annualized past $600 million, driven by steady new patient starts, high persistence, and favorable reimbursement dynamics.
- +7 more takeaways